Use of electronic cigarettes as a risk factor for the different clinical outcomes of COVID-19: A systematic review
DOI:
https://doi.org/10.33448/rsd-v12i9.43251Keywords:
Electronic cigarette; Risk factor; Clinical outcome; COVID-19; Systematic review.Abstract
Objectives: The objective of this study is to systematically review the available epidemiological research published between January and December 2020 in PubMed, Scielo, and LILACS to determine the role of electronic cigarettes as a risk factor for different clinical outcomes of COVID-19. Methods and Material: Systematic review of epidemiological studies published, from January to December 2020, in PubMed, Scielo and LILACS. Registered with PROSPERO, under code: CRD42020226931. Results: Two studies that met the inclusion criteria were included in this review. Both studies were observational and cross-sectional in design. The combined sample size of the studies was 7530 individuals. The results indicated statistically significant associations between electronic cigarette use and COVID-19. When compared to individuals who never used tobacco products, chronic users of e-cigarettes alone were found to be 5.05 times more likely to test positive for COVID-19 (CI 1.82 - 13.96). Similarly, individuals who used both electronic and conventional cigarettes were 6.97 times more likely to test positive for COVID-19 (CI 1.98 - 24.55). Among self-reported infected or previously infected individuals, those who consistently used electronic cigarettes had a 1.30 times greater chance of becoming infected (CI 0.91 - 1.81), while individuals who used both types of smoking had a 1.44 times higher likelihood of infection (CI 1.13 - 1.84). Notably, stronger associations were found for individuals who reported using both electronic and conventional tobacco products, particularly within the last 30 days. Conclusion: There was a positive association between a positive test for COVID-19 and self-reported infection with e-cigarette use.
References
Abrahão, N. M. (2022). The relationship between e-cigarette use and lung disease: an integrative review. Research, Society and Development. 11(1), e13211125030.
Brake, S. J. et al. (2020). Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). Journal of Clinical Medicine. 9(3), 841-848.
Changeux, J. P., Amoura, Z., Rey, F. A. & Miyara M. (2020). A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. Comptes Rendus Biol [Internet], 343(1):33–9.
Chen D. T. H., & Kyriakos, C. N. (2021). Cigarette and e‐cigarettes dual users, exclusive users and covid‐19: Findings from four UK birth cohort studies. International Journal of Environmental Research and Public Health., 18(8).
Ferkol, T. W. et al. (2018). Electronic cigarette use in youths: A position statement of the Forum of International Respiratory Societies. European Respiratory Journal, 51(5).
Gaiha, S. M., Cheng, J. & Halpern-Felsher, B. (2020). Association Between Youth Smoking, Electronic Cigarette Use, and COVID-19. Journal of Adolescent Health, 67(4), 519–523.
Gennaro, F. D. I., et al. (2019). Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. International Journal of Environmental Research and Public Health. p. 17.
Huang, C., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506.
Li, D., Croft, D. P., Ossip, D. J. & Xie, Z. (2020). The association between statewide vaping prevalence and COVID-19. Preventive Medicine Reports, 20.
Lima, C. M. A. O. (2020). Information about the new coronavirus disease (COVID-19). Radiologia Brasileira. 53(2), 10–11.
Martin, M. F. O., et al. (2022). A relação entre a utilização de cigarros eletrônicos e doenças pulmonares: uma revisão integrativa. Research, Society and Development. 11(1), e13211125030.
MERZ W., et al (2022). Electronic cigarette use and perceptions during COVID-19. Respiratory Medicine 200, 106925.
McAlinden K. D., Eapen M. S., Lu, W., Chia, C., Haug, G., & Sohal, S. S. (2020). COVID-19 and vaping: Risk for increased susceptibility to SARS-CoV-2 infection? European Respiratory Journal. 56(1), p. 9.
Rebuli, M. E., Glista-Baker, E., Hoffman J. R., Duffney, P. F., Robinette, C., Speen, A. M., et al. (2021, jan). Electronic-cigarette use alters nasal mucosal immune response to live-attenuated influenza virus: A clinical trial. American Journal of Respiratory Cell and Molecular Biology, 1;64(1);126–37.
Sales, M. P. U., et al. (2018). Update on the approach to smoking in patients with respiratory diseases. Jornal Brasileiro de Pneumologia. 45(3), 17.
Scholl, L., Seth, P., Kariisa, A. M., Wilson, N., & Baldwin, G. (2018). Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017. MMWR Morbidity and Mortality Weekly Report, 21;67(5152).
Scholz, J. R., Abe, T.O. (2019). Cigarro Eletrônico e Doenças Cardiovasculares. Rev Bras Cancerol, 65(3).
Silva, A. L.O., Moreira, J.C., & Martins, S. R. (2020). COVID-19 and smoking: A high-risk association. Cadernos de Saude Pública, 36(5).
Wang, Q., Sundar, I. K., Li, D., Lucas, J. H., Muthumalage, T., McDonough, S. R., et al. (2020, jun). E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR α7 receptor: Role of nAChR α7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation. Respiratory Research, 21(1).
Wu, C., et al. (2020). Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine, 180(7), 934–943.
Yan, Y., Shin, W. I., Pang, Y. X., Meng, Y., Lai, J., You, C., et al. (2020) The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. Int J Environ Res Public Health [Internet]. 17(7):2323.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Wlamir Batista Ribeiro; Bruna Ribeiro Nery; Maristela Rodrigues Sestelo; Rafael Carneiro de Lélis
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
